Aditxt, Inc. Common Stock
ADTXAditxt, Inc. (ADTX) is a biotechnology company focused on developing solutions to monitor, improve, and extend the health of the immune system. The company leverages its proprietary AditxtScore platform to assess immune system health and has interests in vaccine development and immunology research. Aditxt aims to address immune-related health issues through innovative technologies and therapies.
Company News
Aditxt Inc. (NASDAQ:ADTX) shares fell 33.94% in after-hours trading on Tuesday following an SEC Form 4 filing disclosing that major shareholder HRT Financial LP purchased 4.25 million shares at $0.016 per share on June 12. Despite the insider purchase, the stock continued to face selling pressure, closing the regular session down 15.50% at $0.011...
Aditxt announced a definitive business combination agreement to separate its subsidiary Ignite Proteomics into an independent public company valued at approximately $150 million. The transaction aims to unlock value and provide Ignite with greater access to growth capital for its precision oncology platform. However, Aditxt shares fell 28.55% in ...
U.S. stock futures rose on Wednesday after a mixed market close, with uncertainty surrounding November's jobs report and potential Federal Reserve interest rate decisions. Key companies reported earnings with varied results.
Women's health company Evofem Biosciences reported increased net sales of $5.0 million in Q3 2025, a 10% increase from the previous year. The company achieved $1.0 million in operating income, reduced operating expenses by 42%, and advanced strategies to lower manufacturing costs for its products PHEXX and SOLOSEC.
Evofem Biosciences shareholders rejected a proposed merger with Aditxt, leading the company to terminate the merger agreement and pivot towards regaining a national stock listing and securing growth capital.
